{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:48:39Z","timestamp":1793821719942,"version":"4.6.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017590","name":"Universit\u00e4tsklinikum Essen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017590","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Management of patients with migraine who have concomitant medication overuse (MO) or medication overuse headache (MOH) is a major problem in clinical practice. Detoxification of acute analgesics before or during initiation of prophylactic therapy has long been recommended although this concept has recently been questioned. Additionally, relapse after detoxification is a common problem. This real-world study analyses the initial and sustained effectiveness of prophylactic migraine therapy with CGRP (receptor) antibodies without prior detoxification in patients with comorbid MO or MOH for up to one year.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective real-world analysis was performed on 291 patients (episodic migraine (EM) with MO (EM-MO; <jats:italic>n<\/jats:italic>\u2009=\u200935), EM without MO (EM-noMO; <jats:italic>n<\/jats:italic>\u2009=\u200977), chronic migraine (CM) with MOH (CM-MOH; <jats:italic>n<\/jats:italic>\u2009=\u2009109), CM without MOH (CM-noMOH; <jats:italic>n<\/jats:italic>\u2009=\u200970). All patients began treatment with either erenumab (<jats:italic>n<\/jats:italic>\u2009=\u2009173), fremanezumab (<jats:italic>n<\/jats:italic>\u2009=\u200970) or galcanezumab (<jats:italic>n<\/jats:italic>\u2009=\u200948) without prior detoxification. Data were available for up to 12 months of treatment. Responder rates for monthly headache days (MHD), monthly migraine days (MMD) and monthly acute medication intake (AMD) were analysed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>All groups showed a significant reduction in MHD, MMD and AMD at the last observed time point compared to baseline. In patients with CM and MOH, 60.6% (66\/109) no longer fulfilled the definition of MO or MOH and a further 13.8% (15\/109) had only EM-MO. In the EM cohort, 89% (31\/35) of MO patients lost their MO during therapy. MHD and AMD 30% responder rates were comparable for CM-MOH and CM-noMOH (MHD: CM-MOH: 56.0% vs. CM-noMOH: 41.4%, <jats:italic>p<\/jats:italic>\u2009=\u20090.058, AMD: CM-MOH: 66.1% vs. CM-noMOH: 52.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.077). MMD responder rate did not differ significantly (after Bonferroni adjustment) (CM-MOH: 62.4% vs. CM-noMOH: 47.1%, <jats:italic>p<\/jats:italic>\u2009=\u20090.045, \u03b1\u2009=\u20090.017). After successful initiation of therapy, 15.4% of the initial CM-MOH patients relapsed and met the criterion for CM-MOH at the end of follow-up. There were no antibody specific differences in response to therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our data confirms the effectiveness of CGRP antibody treatment in migraine patients with additional MOH or MO in a real-world setting. Low relapse rates after initial successful therapy support an early start of CGRP antibody treatment in patients with MOH or MO.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>No registration, retrospective analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s10194-024-01813-3","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T11:02:35Z","timestamp":1720090955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache\u00a0-\u00a0a retrospective real-world analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Armin","family":"Scheffler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jale","family":"Basten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Fiebelkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang Alexander","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Breunung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Lindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagny","family":"Holle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"1813_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"1813_CR2","doi-asserted-by":"publisher","unstructured":"Togha M, Seyed-Ahadi M, Jafari E, et al. (2020) Estimating quality of life in a headache referral population based on migraine disability assessment scale and headache impact test. CJN. https:\/\/doi.org\/10.18502\/cjn.v19i2.4944.","DOI":"10.18502\/cjn.v19i2.4944"},{"key":"1813_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1129-2377-15-31","volume":"15","author":"TJ Steiner","year":"2014","unstructured":"Steiner TJ, Stovner LJ, Katsarava Z et al (2014) The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 15:31","journal-title":"J Headache Pain"},{"key":"1813_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ et al (2012) The cost of headache disorders in Europe: the Eurolight project. Euro J Neurol 19:703\u2013711. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x","journal-title":"Euro J Neurol"},{"key":"1813_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nrneurol.2016.124","volume":"12","author":"H-C Diener","year":"2016","unstructured":"Diener H-C, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575\u2013583. https:\/\/doi.org\/10.1038\/nrneurol.2016.124","journal-title":"Nat Rev Neurol"},{"key":"1813_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/j.1468-2982.2008.01711.x","volume":"29","author":"K Hagen","year":"2009","unstructured":"Hagen K, Albretsen C, Vilming S et al (2009) Management of medication overuse headache: 1-year randomized multicentre open-label trial. Cephalalgia 29:221\u2013232. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01711.x","journal-title":"Cephalalgia"},{"key":"1813_CR7","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","volume":"77","author":"LN Carlsen","year":"2020","unstructured":"Carlsen LN, Munksgaard SB, Nielsen M et al (2020) Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial. JAMA Neurol 77:1069. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1179","journal-title":"JAMA Neurol"},{"key":"1813_CR8","doi-asserted-by":"publisher","first-page":"033310242311569","DOI":"10.1177\/03331024231156922","volume":"43","author":"S Giri","year":"2023","unstructured":"Giri S, Tronvik E, Linde M et al (2023) Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: a systematic review and meta-analysis. Cephalalgia 43:033310242311569. https:\/\/doi.org\/10.1177\/03331024231156922","journal-title":"Cephalalgia"},{"key":"1813_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000504620","volume":"82","author":"H Liu","year":"2019","unstructured":"Liu H, Zhang M, Chen X et al (2019) Rates and predictors of relapse in medication overuse headache: a clinic-based study from China. Eur Neurol 82:68\u201374. https:\/\/doi.org\/10.1159\/000504620","journal-title":"Eur Neurol"},{"key":"1813_CR10","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1111\/j.1468-2982.2008.01659.x","volume":"28","author":"P Rossi","year":"2008","unstructured":"Rossi P, Faroni J, Nappi G (2008) Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 28:1196\u20131200. https:\/\/doi.org\/10.1111\/j.1468-2982.2008.01659.x","journal-title":"Cephalalgia"},{"key":"1813_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/j.1468-2982.2007.01432.x","volume":"27","author":"J Zidverc-Trajkovic","year":"2007","unstructured":"Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z et al (2007) Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 27:1219\u20131225. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01432.x","journal-title":"Cephalalgia"},{"key":"1813_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1468-2982.2004.00789.x","volume":"25","author":"Z Katsarava","year":"2005","unstructured":"Katsarava Z, Muessig M, Dzagnidze A et al (2005) Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia 25:12\u201315. https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00789.x","journal-title":"Cephalalgia"},{"key":"1813_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-024-01725-2","volume":"25","author":"AJ Starling","year":"2024","unstructured":"Starling AJ, Cady R, Buse DC et al (2024) Harris poll migraine report card: population-based examination of high-frequency headache\/migraine and acute medication overuse. J Headache Pain 25:26. https:\/\/doi.org\/10.1186\/s10194-024-01725-2","journal-title":"J Headache Pain"},{"key":"1813_CR14","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1212\/CPJ.0000000000001037","volume":"11","author":"TJ Schwedt","year":"2021","unstructured":"Schwedt TJ, Buse DC, Argoff CE et al (2021) Medication overuse and headache burden: results from the CaMEO study. Neur Clin Pract 11:216\u2013226. https:\/\/doi.org\/10.1212\/CPJ.0000000000001037","journal-title":"Neur Clin Pract"},{"key":"1813_CR15","doi-asserted-by":"publisher","first-page":"033310242211502","DOI":"10.1177\/03331024221150235","volume":"43","author":"A Alpuente","year":"2023","unstructured":"Alpuente A, Torres-Ferrus M, Terwindt GM (2023) Preventive CGRP-targeted therapies for chronic migraine with and without medication-overuse headache. Cephalalgia 43:033310242211502. https:\/\/doi.org\/10.1177\/03331024221150235","journal-title":"Cephalalgia"},{"key":"1813_CR16","doi-asserted-by":"publisher","first-page":"1129439","DOI":"10.3389\/fneur.2023.1129439","volume":"14","author":"AV Krymchantowski","year":"2023","unstructured":"Krymchantowski AV, Jevoux C, Krymchantowski AG, Silva-N\u00e9to RP (2023) Monoclonal antibodies for chronic migraine and medication overuse headache: A real-world study. Front Neurol 14:1129439.\u00a0https:\/\/doi.org\/10.3389\/fneur.2023.1129439","journal-title":"Front Neurol"},{"key":"1813_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/03331024211067791","volume":"42","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V et al (2022) Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache. Cephalalgia 42:645\u2013653. https:\/\/doi.org\/10.1177\/03331024211067791","journal-title":"Cephalalgia"},{"key":"1813_CR18","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s10072-021-05426-5","volume":"43","author":"U Pensato","year":"2022","unstructured":"Pensato U, Baraldi C, Favoni V et al (2022) Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache. Neurol Sci 43:1273\u20131280. https:\/\/doi.org\/10.1007\/s10072-021-05426-5","journal-title":"Neurol Sci"},{"key":"1813_CR19","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1111\/j.1468-2982.2007.01326.x","volume":"27","author":"H-C Diener","year":"2007","unstructured":"Diener H-C, Bussone G, Oene JV et al (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814\u2013823. https:\/\/doi.org\/10.1111\/j.1468-2982.2007.01326.x","journal-title":"Cephalalgia"},{"key":"1813_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.WNF.000022888.49044.99","volume":"29","author":"D Mei","year":"2006","unstructured":"Mei D, Ferraro D, Zelano G et al (2006) Topiramate and triptans revert chronic migraine with medication overuse to episodic migraine. Clin Neuropharmacol 29:269\u2013275. https:\/\/doi.org\/10.1097\/01.WNF.000022888.49044.99","journal-title":"Clin Neuropharmacol"},{"key":"1813_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","volume":"331","author":"SD Silberstein","year":"2013","unstructured":"Silberstein SD, Blumenfeld AM, Cady RK et al (2013) OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 331:48\u201356. https:\/\/doi.org\/10.1016\/j.jns.2013.05.003","journal-title":"J Neurol Sci"},{"key":"1813_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42466-022-00200-0","volume":"4","author":"H-C Diener","year":"2022","unstructured":"Diener H-C, Kropp P, Dresler T et al (2022) Management of medication overuse (MO) and medication overuse headache (MOH) S1 guideline. Neurol Res Pract 4:37. https:\/\/doi.org\/10.1186\/s42466-022-00200-0","journal-title":"Neurol Res Pract"},{"key":"1813_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11910-023-01278-y","volume":"23","author":"MA Hird","year":"2023","unstructured":"Hird MA, Sandoe CH (2023) Medication overuse headache: an updated review and clinical recommendations on management. Curr Neurol Neurosci Rep 23:389\u2013398. https:\/\/doi.org\/10.1007\/s11910-023-01278-y","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1813_CR24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-021-01328-1","volume":"22","author":"E Caronna","year":"2021","unstructured":"Caronna E, Gallardo VJ, Alpuente A et al (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 22:120. https:\/\/doi.org\/10.1186\/s10194-021-01328-1","journal-title":"J Headache Pain"},{"key":"1813_CR25","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1046\/j.1526-4610.1996.3607433.x","volume":"36","author":"L Pini","year":"1996","unstructured":"Pini L, Bigarelli M, Vitale G, Sternieri E (1996) Headaches associated with chronic use of analgesics: a therapeutic approach. Headache 36:433\u2013439. https:\/\/doi.org\/10.1046\/j.1526-4610.1996.3607433.x","journal-title":"Headache"},{"key":"1813_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jocn.2019.09.006","volume":"70","author":"X Yuan","year":"2019","unstructured":"Yuan X, Jiang W, Ren X et al (2019) Predictors of relapse in patients with medication overuse headache in Shanghai: a retrospective study with a 6-month follow-up. J Clin Neurosci 70:33\u201336. https:\/\/doi.org\/10.1016\/j.jocn.2019.09.006","journal-title":"J Clin Neurosci"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01813-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01813-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01813-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T07:02:20Z","timestamp":1753945340000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01813-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1813"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01813-3","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"9 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analysis was approved by the independent ethics committee of the University Hospital Essen (19\u20139004-BO) and all patients gave written consent to general analysis of their personal and clinical data. Because of retrospective analysis of internal routine data, no special written informed consent was necessary for this specific analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DH has received scientific support and\/or honoraria from Biogen, Novartis, Lilly, Sanofi-Aventis, Teva, Allergan, Hormosan.CK has received honoraria, a consulting or advisory role to declare from Novartis and Teva.MN received travel fees from Licher MT.AS has received travel fees from Teva and honoraria from Novartis (advisory board).JB, WB, DF, VB, DL, LM and HS declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"109"}}